LON:HVO hVIVO (HVO) Share Price, News & Analysis GBX 28.40 +0.40 (+1.43%) (As of 12:31 PM ET) Add Compare Share Share Today's Range 28▼ 2950-Day Range 26.90▼ 30.6052-Week Range 16.76▼ 32Volume13.54 million shsAverage Volume3.39 million shsMarket Capitalization£193.23 millionP/E Ratio946.67Dividend Yield0.70%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendHeadlinesStock AnalysisChartCompetitorsDividendHeadlines Get hVIVO alerts: Email Address Ad Monetary GoldBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. About hVIVO Stock (LON:HVO)hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.Written by Jeffrey Neal JohnsonRead More HVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HVO Stock News HeadlinesSeptember 11, 2024 | msn.comHow much more passive income could be made from Aviva shares than from the FTSE 100 as a whole?September 11, 2024 | fool.co.ukHere’s 1 UK stock that I think will soar in the next FTSE bull marketSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.September 10, 2024 | americanbankingnews.comhVIVO (LON:HVO) Stock Passes Below Fifty Day Moving Average of $28.95July 30, 2024 | msn.comAre penny stocks still worth buying in 2024?July 21, 2024 | msn.comHere’s how I’d invest to try and unlock £63,000 in annual passive incomeMay 28, 2024 | msn.comCan this £3,000 bed help me sleep like a billionaire?May 3, 2024 | morningstar.comhVIVO PLC HVOSeptember 16, 2024 | Monetary Gold (Ad)Biden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.April 21, 2024 | proactiveinvestors.com.auhVIVO primed for success, says US investmentApril 15, 2024 | uk.finance.yahoo.com2 under-the-radar growth stocks I’ve just bought for my Stocks and Shares ISAApril 10, 2024 | finance.yahoo.comIs hVIVO plc's (LON:HVO) Recent Stock Performance Tethered To Its Strong Fundamentals?April 9, 2024 | msn.comIs hVIVO still a top UK stock for growth after today’s full-year results?April 9, 2024 | finance.yahoo.comhVIVO achieves record revenue and initiates dividend policy following successful yearMarch 15, 2024 | msn.comTesla bearishness is overdone, and the company's board should do these 3 things to send the stock soaring again, Wedbush saysMarch 13, 2024 | msn.comSam Altman said he texted Elon Musk after the billionaire sued himMarch 13, 2024 | msn.comFTSE 100 ends higher as UK economy returns to growthMarch 13, 2024 | uk.style.yahoo.comStock market today: US stocks hold steady after rally as investors wait on more economic dataSee More Headlines Receive HVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for hVIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/19/2018Today9/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HVO Previous SymbolLON:RVG CUSIPN/A CIKN/A Webhvivo.com Phone+44-20-77561300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX 0.03 Trailing P/E Ratio953.33 Forward P/E Ratio17.89 P/E GrowthN/ANet Income£16.11 million Net Margins27.47% Pretax MarginN/A Return on Equity59.09% Return on Assets9.58% Debt Debt-to-Equity Ratio36.50 Current Ratio1.48 Quick Ratio1.16 Sales & Book Value Annual Sales£58.67 million Price / Sales3.32 Cash FlowGBX 5.79 per share Price / Cash Flow4.94 Book ValueGBX 5 per share Price / Book5.72Miscellaneous Outstanding Shares680,370,000Free FloatN/AMarket Cap£194.59 million OptionableNot Optionable Beta0.97 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Yamin Mohammed Khan Ph.D. (Age 54)CEO & Director Mr. Stephen PinkertonCFO & Exec. DirectorMr. Andrew CatchpoleChief Scientific OfficerDr. Maurice N. Treacy Ph.D.Chief Commercial OfficerMs. Teja Marathe-SarvadikarHead of QAKey CompetitorsErgomedLON:ERGOSilence TherapeuticsLON:SLNPureTech HealthLON:PRTCOxford BiomedicaLON:OXBHorizon Discovery Group plc (HZD.L)LON:HZDView All CompetitorsInsidersCathal FrielSold 21,159,176 sharesTotal: £613.62 M ($29.00/share) HVO Stock Analysis - Frequently Asked Questions How have HVO shares performed this year? hVIVO's stock was trading at GBX 23.75 at the start of the year. Since then, HVO shares have increased by 19.6% and is now trading at GBX 28.40. View the best growth stocks for 2024 here. How were hVIVO's earnings last quarter? hVIVO plc (LON:HVO) posted its earnings results on Thursday, April, 19th. The company reported ($16.50) earnings per share for the quarter, missing the consensus estimate of ($10.90) by $5.60. hVIVO had a trailing twelve-month return on equity of 59.09% and a net margin of 27.47%. How do I buy shares of hVIVO? Shares of HVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of hVIVO own? Based on aggregate information from My MarketBeat watchlists, some other companies that hVIVO investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Falanx Group (FLX), IQE (IQE), Scirocco Energy Plc (SOLO.L) (SOLO) and CyanConnode (CYAN). This page (LON:HVO) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding hVIVO plc Please log in to your account or sign up in order to add this asset to your watchlist. Share hVIVO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.